Announcements Trials

Browse Landscape

Phase

Phase 3 6 Phase 2 4 Phase 1/2 3 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Specimen Handling 108 Magnetic Resonance Spectroscopy 77 Biopsy 76 pembrolizumab 59 Cyclophosphamide 49 fludarabine 40 Carboplatin 25 Nivolumab 24 Cetuximab 23 venetoclax 21 Radiotherapy 21 Cisplatin 21 Bevacizumab 20 atezolizumab 18 X-Rays 18 Radiation 17 Ipilimumab 17 fludarabine phosphate 16 Fluorouracil 16 Gemcitabine 15 Temozolomide 14 Paclitaxel 14 Leucovorin 14 Irinotecan 14 Cytarabine 14 durvalumab 13 Pemetrexed 13 Azacitidine 13 Oxaliplatin 12 CTLA-4 Antigen 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × belzutifan × 30 days × Clear all

NCT04846920 2026-05-22

MK-6482-018

Merck Sharp & Dohme LLC

Phase 1 Completed

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡